Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment
Neurological Sciences · 2025
DOI: 10.1007/s10072-024-07896-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2025. Verfasst von Yanning Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Rituximab, Neuromyelitis Optica, Nomograms, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Nankai University, Tianjin, 300071, China.
- Department of Neurology, Chinese PLA General Hospital Second Medical Centre, Beijing, 100853, China.
- Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
- Department of Neurology, Chinese PLA General Hospital First Medical Centre, 28 Fuxing Road, Beijing, 100853, China.
- Department of Neurology, Chinese PLA General Hospital First Medical Centre, 28 Fuxing Road, Beijing, 100853, China. huangdehui@gmail.com.
Zitieren
APA
Huang, Y., Wu, L., Sun, H., Gao, S., Huang, D., & Zhang, X. (2025). Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment. Neurological Sciences. https://doi.org/10.1007/s10072-024-07896-9
Vancouver
Huang Y, Wu L, Sun H, Gao S, Huang D, Zhang X. Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment. Neurological Sciences. 2025. doi:10.1007/s10072-024-07896-9
BibTeX
@article{Huang2025,
author = {Huang, Yanning and Wu, Lei and Sun, Hui and Gao, Sai and Huang, Dehui and Zhang, Xi},
title = {Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-024-07896-9}
}
EUVIMED